CLYM (Climb Bio) Research & Development: $38.76 Mil (TTM As of Mar. 2026)


CLYM Climb Bio Inc CLYM
22 GF Score
Price $12.75
! 2 Warning Signs
View Full Analysis

What is Climb Bio Research & Development?

Climb Bio CLYM +3.83% 22 Research & Development is $38.76 Mil as of Mar. 2026. GuruFocus rates CLYM with a GF Score™ of 22/100. The stock has 2 warning signs investors should review.

Research & Development is the aggregate amount of research and development expenses during the year. Climb Bio's Research & Development for the three months ended in Mar. 2026 was $9.37 Mil. Its Research & Development for the trailing twelve months (TTM) ended in Mar. 2026 was $38.76 Mil.

Climb Bio  (NAS:CLYM) Research & Development Explanation

If competitive advantage is created by a patent or tech advantage, at some point it will disappear.

High R&D usually dictates high SG&A which threatens the competitive advantage.

Climb Bio Research & Development Related Terms

Climb Bio Research & Development Historical Data

* Premium members only.

The historical data trend for Climb Bio's Research & Development can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Climb Bio Research & Development Chart

Climb Bio Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Research & Development
Get a 7-Day Free Trial 23.32 26.21 15.41 14.34 46.71

Climb Bio Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Research & Development Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 17.33 6.58 9.07 13.74 9.37
CLYM
22GF Score
Climb Bio Inc CLYM
Research & Development is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Climb Bio Research & Development Calculation

This is the expense the company spent on research and development.

Research & Development for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $38.76 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Research & Development →
What does a Research & Development of $38.76 Mil mean?
Climb Bio (CLYM) has a Research & Development of $38.76 Mil as of Mar. 2026. Research and development expense is the total cost for research and development activities. View historical data on Climb Bio and its competitors.
Is Climb Bio's Research & Development too high?
Climb Bio's current Research & Development is $38.76 Mil. Overall, Climb Bio has a GF Score™ of 22/100, reflecting its overall financial health beyond just this single metric.
How does Climb Bio's Research & Development compare to ACRS and CABA?
Climb Bio's Research & Development of $38.76 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Research & Development for a Biotechnology company?
A good Research & Development depends on the Biotechnology industry context. However, Research & Development should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Research & Development mean?
A high Research & Development can signal that a stock is expensive relative to its fundamentals. Research and development expense is the total cost for research and development activities. View historical data on Climb Bio and its competitors. Climb Bio's current Research & Development is $38.76 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Climb Bio stock overvalued right now?
Climb Bio (CLYM) has a current Research & Development of $38.76 Mil. The current Research & Development is $38.76 Mil. Climb Bio's overall GF Score™ is 22/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Research & Development calculated?
Research & Development is calculated from a company's financial statements. For Climb Bio (CLYM), the current Research & Development is $38.76 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Climb Bio Business Description

Address 20 William Street, Suite 145, Wellesley Hills, MA, USA, 02481
Climb Bio Inc is a clinical-stage biotechnology company focused on developing therapeutics for patients with immune-mediated diseases. Its pipeline includes Budoprutug, an anti-CD19 monoclonal antibody being developed for B-cell mediated diseases such as primary membranous nephropathy, immune thrombocytopenia, and systemic lupus erythematosus, and CLYM116, an anti-APRIL monoclonal antibody being developed for the treatment of IgA nephropathy.
22GF Score

Get the complete analysis for CLYM

Research & Development is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$12.75
Price